Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Ionis Pharmaceuticals Inc (NASDAQ:IONS)

35.39
Delayed Data
As of Feb 05
 -0.17 / -0.48%
Today’s Change
32.75
Today|||52-Week Range
77.80
-42.85%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$4.3B

Company Description

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of antisense drug discovery. It operates through two segments: Drug Discovery & Development Operations and Akcea. The Drug Discovery & Development Operations segment provides drugs to treat a variety of health conditions, with an emphasis on cardiovascular, metabolic, severe and rare diseases, including neurological disorders, and cancer. The Akcea segment, which is a subsidiary, focuses on the clinical development of ISIS-APOCIIIRx, ISIS-APO(a)Rx and ISIS-ANGPTL3Rx, as well as more potent follow on drugs from these programs. The company was founded by Stanley T. Crooke in January 1989 and is headquartered in Carlsbad, CA.

Contact Information

Ionis Pharmaceuticals, Inc.
2855 Gazelle Court
Carlsbad California 92010
P:(760) 931-9200
Investor Relations:
(760) 603-2331

Employees

Shareholders

Mutual fund holders52.46%
Other institutional36.20%
Individual stakeholders0.68%

Top Executives

Stanley T. CrookeChairman, President & Chief Executive Officer
B. Lynne ParshallChief Operating Officer & Director
Elizabeth L. HougenChief Financial Officer & SVP-Finance
C. Frank BennettSenior Vice President-Antisense Research
Brett P. MoniaSenior VP-Drug Discovery & Corporate Development